Company news: Caplin Point Laboratories

| Updated on April 08, 2019 Published on April 08, 2019

Caplin Point Laboratories on Monday said its subsidiary has entered into a licence and supply agreement with Baxter Healthcare Corporation for a portfolio of five generic injectables. As a part of the deal, Caplin Steriles, a wholly-owned subsidiary of Caplin Point Laboratories, will out-license five of its injectable Abbreviated New Drug Applications to Baxter Healthcare Corporation. All these ANDAs have been developed in-house and Caplin is keen to license them to Baxter, which has an excellent sales and marketing infrastructure in the US for commercialisation of these products. Shares of Caplin Point closed 0.19 per cent lower at ₹386.55 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 08, 2019
This article is closed for comments.
Please Email the Editor